Rufinamide in refractory childhood epileptic encephalopathies other than Lennox–Gastaut syndrome
- 17 January 2011
- journal article
- clinical trial
- Published by Wiley in European Journal of Neurology
- Vol. 18 (2) , 246-251
Abstract
Background: To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood‐onset epileptic encephalopathies other than Lennox–Gastaut syndrome.Methods: Thirty‐eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7 ± 8.3, median 12.5), all affected by different types of childhood‐onset refractory epileptic encephalopathies other than Lennox–Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3–26 months).Results: Fifteen of 38 patients (39.5%) had a ≥50% seizure reduction in countable seizures. Complete seizure freedom was achieved in one of these patients (2.6%). Three patients (7.9%) had a 25–49% seizure reduction, whilst seizure frequency remained unchanged in 15 (39.5%) and increased in five patients (13.1%). Eleven patients (28.9%) reported adverse side effects. Vomiting was reported in five patients (13.1%); drowsiness, decreased appetite and irritability with migraine manifested in other four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well‐tolerated adjunctive drug for the treatment of refractory childhood‐onset epileptic encephalopathies other than Lennox–Gastaut syndrome. Rufinamide was most effective in patients with drop‐attacks and (bi)frontal spike–wave discharges.Keywords
This publication has 11 references indexed in Scilit:
- First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsyEpilepsy & Behavior, 2010
- Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo‐controlled trialEpilepsia, 2009
- Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experienceEpilepsy & Behavior, 2009
- The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure modelsEpilepsia, 2008
- Rufinamide: Clinical pharmacokinetics and concentration–response relationships in patients with epilepsyEpilepsia, 2008
- Rufinamide for generalized seizures associated with Lennox–Gastaut syndromeNeurology, 2008
- RufinamideNeurotherapeutics, 2007
- Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsyEpilepsy Research, 2001
- Proposal for Revised Classification of Epilepsies and Epileptic SyndromesEpilepsia, 1989
- Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic SeizuresEpilepsia, 1981